Abstract
We report 14 cases of secondary myelodysplastic syndromes (sMDS) following treatment with azathioprine for non-malignant disorders. Long-term treatment with azathioprine seems to be associated with an increased risk of MDS and subsequent leukemic transformation.
Publication types
-
Letter
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Autoimmune Diseases / drug therapy
-
Azathioprine / adverse effects*
-
Azathioprine / therapeutic use
-
Cell Transformation, Neoplastic / chemically induced
-
Chromosomes, Human, Pair 7 / ultrastructure*
-
Female
-
Heart Transplantation
-
Humans
-
Immunosuppressive Agents / adverse effects*
-
Immunosuppressive Agents / therapeutic use
-
In Situ Hybridization, Fluorescence
-
Kidney Transplantation
-
Male
-
Middle Aged
-
Monosomy*
-
Myelodysplastic Syndromes / chemically induced*
-
Myelodysplastic Syndromes / genetics
-
Postoperative Complications / chemically induced
-
Retrospective Studies
-
Rheumatic Diseases / drug therapy
-
Translocation, Genetic*
Substances
-
Immunosuppressive Agents
-
Azathioprine